Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

DecisionDx-Melanoma Validated Across Cutaneous Melanoma Subtypes In 13,560 Patients With Results To Be Presented By Castle Biosciences At Dermatology Conference

Author: Benzinga Newsdesk | October 24, 2025 03:16am

This new histological subtype data confirms DecisionDx-Melanoma's clinical value across the spectrum of melanoma

Castle Biosciences will also present validation data on its atopic dermatitis pipeline test

Posted In: CSTL